Sign In
Buy WST
$316.31
+4.14 (+1.33%)
At Close: Jun 03, 2026
West Pharmaceutical Services, Inc. (WST) Q3 2024 Earnings Call Transcript
03:02pm, Thursday, 24'th Oct 2024
West Pharmaceutical Services, Inc. (NYSE:WST ) Q3 2024 Results Earnings Conference Call October 24, 2024 9:00 AM ET Company Participants John Sweeney - Vice President, Investor Relations Eric Green -
West Pharmaceutical's Q3 Performance Shows Rising Demand For Syringes, Company Boosts Annual Forecast And Dividend
01:09pm, Thursday, 24'th Oct 2024
On Thursday, West Pharmaceutical Services, Inc. WST reported adjusted EPS of $1.85, down from $2.16 a year ago, beating the consensus of $1.50.
West Pharmaceutical Stock Gains on Q3 Earnings Beat & Raised Guidance
12:10pm, Thursday, 24'th Oct 2024
WST's third-quarter results reflect a recovery in the Proprietary Products segment following elevated customer destocking, hurting sales in the second quarter.
West Pharmaceutical Services (WST) Tops Q3 Earnings and Revenue Estimates
08:11am, Thursday, 24'th Oct 2024
West Pharmaceutical Services (WST) came out with quarterly earnings of $1.85 per share, beating the Zacks Consensus Estimate of $1.51 per share. This compares to earnings of $2.16 per share a year ago
West Pharmaceutical raises annual profit forecast on demand for medical supplies
06:46am, Thursday, 24'th Oct 2024
West Pharmaceutical Services raised its annual profit forecast on Thursday, after beating Wall Street estimates for quarterly revenue and profit, banking on rising demand for cartridges and syringes u
West Announces Third-Quarter 2024 Results, Increases Fiscal Year 2024 Guidance and Declares Fourth-Quarter 2024 Dividend
06:00am, Thursday, 24'th Oct 2024
- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa.
EXTON, Pa. , Oct. 22, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced participation i
What's in Store for West Pharmaceutical in Q3 Earnings?
10:50am, Monday, 21'st Oct 2024
WST's third-quarter 2024 results are likely to reflect weakness in its Proprietary Products business. Unfavorable currency movements might have hurt the top and bottom lines.
Earnings Preview: West Pharmaceutical Services (WST) Q3 Earnings Expected to Decline
11:06am, Thursday, 17'th Oct 2024
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
West to Host Third-Quarter 2024 Conference Call
06:00am, Thursday, 10'th Oct 2024
EXTON, Pa. , Oct. 10, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will rele
West Wins Heart of Pharma Award at 2024 CPHI Pharma Awards
06:00am, Wednesday, 09'th Oct 2024
EXTON, Pa. , Oct. 9, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, is pleased to announce that it h
West to Attend and Showcase Industry Leadership in Packaging and Containment at CPHI Worldwide Conference
06:00am, Monday, 07'th Oct 2024
EXTON, Pa. , Oct. 7, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced its participati
West to Participate in Upcoming Investor Conference
06:00am, Thursday, 05'th Sep 2024
EXTON, Pa. , Sept. 5, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will pr
Final Trade: WST, OIH, META, GOOGL
07:04pm, Friday, 26'th Jul 2024
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
West Pharmaceutical: Continued Destocking And A High Valuation Post Q2 Results (Rating Maintained)
02:00pm, Thursday, 25'th Jul 2024
West Pharmaceutical Q2'24 results missed expectations, with lower revenues and EPS missing guidance, impacted by destocking and poor sales in various segments. Management remains optimistic for the ba
